1. Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions
   Swatishree Sradhanjali et al, 2017, PLOS ONE CrossRef
2. p53 and glucose metabolism: an orchestra to be directed in cancer therapy
   Ana Sara Gomes et al, 2018, Pharmacological Research CrossRef
3. Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: a mechanistic hypothesis
   Russel J. Reiter et al, 2020, Cellular and Molecular Life Sciences CrossRef
4. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy
   Saleha Anwar et al, 2021, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
5. Autophagy in cancer resistance to paclitaxel: Development of combination strategies
   Jan Škubník et al, 2023, Biomedicine & Pharmacotherapy CrossRef
6. Severe hypoxia increases expression of ATM and DNA-PKcs and it increases their activities through Src and AMPK signaling pathways
   Takuma Hashimoto et al, 2018, Biochemical and Biophysical Research Communications CrossRef
7. Restoration of mitochondria function as a target for cancer therapy
   Tariq A. Bhat et al, 2015, Drug Discovery Today CrossRef
8. Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines
   Aistė Skeberdytė et al, 2018, Scientific Reports CrossRef
9. Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer
   Peter W Stacpoole, 2017, JNCI: Journal of the National Cancer Institute CrossRef
10. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer
    Abdulmelik Aytatli et al, 2022, Cellular Oncology CrossRef
11. Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site
    Tiziana Masini et al, 2016, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef